Ascelia Pharma AB (publ) (STO:ACE)
Sweden · Delayed Price · Currency is SEK | Market Cap | 385.25M -12.2% |
| Revenue (ttm) | n/a |
| Net Income | -70.90M |
| EPS | -0.59 |
| Shares Out | 133.54M |
| PE Ratio | n/a |
| Forward PE | 14.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 398,078 |
| Average Volume | 630,566 |
| Open | 2.910 |
| Previous Close | 2.900 |
| Day's Range | 2.845 - 2.940 |
| 52-Week Range | 2.530 - 5.230 |
| Beta | 0.89 |
| RSI | 43.16 |
| Earnings Date | May 12, 2026 |
About Ascelia Pharma AB
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in M... [Read more]
Financial Performance
Financial StatementsNews
Ascelia Pharma AB Transcript: ABGSC Investor Days
Orviglance, a manganese-based MRI agent for rare cancer patients with severe renal disease, is nearing FDA approval with a PDUFA date in early July. The company is actively seeking commercialization partners and holds Orphan Drug Designation, ensuring market exclusivity. Market research and industry trends strongly support adoption.
Ascelia Pharma AB Transcript: ABGSC Investor Days
Orviglance, a manganese-based MRI agent for rare cancer patients with severe renal disease, is nearing FDA approval with a PDUFA date in early July. The company is actively seeking commercialization partners and holds Orphan Drug Designation, ensuring market exclusivity. Market research and industry trends strongly support adoption.
Q1 2026 Ascelia Pharma AB Earnings Presentation Transcript
Q1 2026 Ascelia Pharma AB Earnings Presentation Transcript
Ascelia Pharma AB Earnings Call Transcript: Q1 2026
Q1 saw steady operating losses and a strengthened cash position after a SEK 20 million raise. Orviglance is on track for FDA approval in July, with strong clinical data and active partnership discussions. Market trends favor non-gadolinium agents, supporting a positive outlook.
Ascelia Pharma AB Quarterly report: Q1 2026
Ascelia Pharma AB has published its Q1 2026 quarterly earnings report on May 13, 2026.
Ascelia Pharma AB Slides: Q1 2026
Ascelia Pharma AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Ascelia Pharma AB Earnings Call Transcript: Q1 2026
Q1 saw steady operating losses and a strengthened cash position after a SEK 20 million raise. Orviglance is on track for FDA approval in July, with strong clinical data and active partnership discussions. Market trends favor non-gadolinium agents, supporting a positive outlook.
Ascelia Pharma AB Quarterly report: Q1 2026
Ascelia Pharma AB has published its Q1 2026 quarterly earnings report on May 13, 2026.
Ascelia Pharma AB Slides: Q1 2026
Ascelia Pharma AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Ascelia Pharma AB (FRA:7ZA) Q1 2026 Earnings Call Highlights: Progress Towards FDA Approval and ...
Ascelia Pharma AB (FRA:7ZA) Q1 2026 Earnings Call Highlights: Progress Towards FDA Approval and Financial Challenges
Q1 2026 Ascelia Pharma AB Earnings Call Transcript
Q1 2026 Ascelia Pharma AB Earnings Call Transcript
Ascelia Pharma AB Earnings Call Transcript: Q1 2026
Q1 2026 saw continued progress toward FDA approval and commercialization partnership for Orviglance, with a PDUFA date set for July 3, 2026. Operating loss decreased to SEK 17 million, and a SEK 20 million share issue extended the cash runway into 2027.
Ascelia Pharma AB Quarterly report: Q1 2026
Ascelia Pharma AB has published its Q1 2026 quarterly earnings report on May 12, 2026.
Ascelia Pharma AB Slides: Q1 2026
Ascelia Pharma AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
Ascelia Pharma AB Earnings Call Transcript: Q1 2026
Q1 2026 saw progress toward FDA approval and commercialization of Orviglance, with strong clinical data and an extended cash runway into 2027 after a SEK 20 million share issue. Oncoral remains in the pipeline with phase II plans in gastric cancer.
Ascelia Pharma AB Quarterly report: Q1 2026
Ascelia Pharma AB has published its Q1 2026 quarterly earnings report on May 12, 2026.
Ascelia Pharma AB Slides: Q1 2026
Ascelia Pharma AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
Ascelia Pharma AB Transcript: DNB Carnegie Healthcare Seminar 2026
Orviglance, a manganese-based liver MRI agent for patients with severe renal disease, is under FDA review with a July 3 PDUFA date and strong Phase 3 data. Commercialization will rely on partnerships, and the company is also advancing Oncoral, an oral irinotecan, into further development.
Ascelia Pharma AB Transcript: DNB Carnegie Healthcare Seminar 2026
Orviglance, a manganese-based liver MRI agent for patients with severe renal disease, is under FDA review with a July 3 PDUFA date and strong Phase 3 data. Commercialization will rely on partnerships, and the company is also advancing Oncoral, an oral irinotecan, into further development.
Ascelia Pharma AB (FRA:7ZA) Q4 2025 Earnings Call Highlights: FDA Review Progress and Strategic ...
Ascelia Pharma AB (FRA:7ZA) Q4 2025 Earnings Call Highlights: FDA Review Progress and Strategic Challenges
Q4 2025 Ascelia Pharma AB Earnings Call Transcript
Q4 2025 Ascelia Pharma AB Earnings Call Transcript
Ascelia Pharma AB Earnings Call Transcript: Q4 2025
Lead program Orviglance is in FDA review with a decision expected by July, targeting a significant unmet need in liver imaging for cancer patients with severe renal impairment. Financials show a SEK 16 million Q4 loss and SEK 50 million cash, with partnership discussions and launch preparations progressing well.
Ascelia Pharma AB Annual report: Q4 2025
Ascelia Pharma AB has published its Q4 2025 annual report on February 6, 2026.
Ascelia Pharma AB Quarterly report: Q4 2025
Ascelia Pharma AB has published its Q4 2025 quarterly earnings report on February 6, 2026.
Ascelia Pharma AB Slides: Q4 2025
Ascelia Pharma AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 6, 2026.